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Abstract 
Mutations in the ARX gene are associated with a broad spectrum of disorders, including nonsyndromic 
X-linked mental retardation, sometimes associated with epilepsy, as well as syndromic forms with 
brain abnormalities and abnormal genitalia. Furthermore, ARX mutations have been described in a 
few patients with autism or autistic features. In this study, we screened the ARX gene in 226 male 
patients with autism spectrum disorders and mental retardation; 42 of the patients had epilepsy. The 
mutation analysis was performed by direct sequencing of all exons and flanking regions. No ARX 
mutations were identified in any of the patients tested. These findings indicate that mutations in the 
ARX gene are very rare in autism. 
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INTRODUCTION 
Mutations in the X-linked gene Aristaless related homeobox (ARX) have recently been shown to 
cause mental retardation, either isolated or associated with a broad spectrum of neurological 
disorders. The first ARX mutations were found in families with mental retardation and various forms of 
epilepsy, including West syndrome (infantile spasms, hypsarrhythmia, and mental retardation), 
myoclonic epilepsy, or Partington syndrome (dystonic movements of the hands, mental retardation, 
and seizures) (Stromme et al., 2002b). Subsequently, ARX mutations have been reported in familial 
and sporadic cases of nonsyndromic mental retardation (Bienvenu et al., 2002), X-linked 
lissencephaly with abnormal genitalia (Kitamura et al., 2002), agenesis of the corpus callosum, 
hydranencephaly, ataxia, and different types of epilepsy (for review see Suri 2005). Furthermore, the 
reevaluation of two families with an ARX mutation originally diagnosed with X-linked mental 
retardation (Stromme et al., 2002b) showed that one patient had autism and three had autistic 
features (Turner et al., 2002). This striking phenotypic variability is partly explained by the type of 
mutation, with duplications and missense mutations resulting in mental retardation alone or with 
epilepsy or autism, whereas loss-of-function mutations result in more severe phenotypes with brain 
malformations and abnormal genitalia (Suri 2005). The most frequently reported mutation is a 24-bp 
duplication in exon 2, c.428-451dup(24 bp), which results in the expansion of a polyalanine tract and 
accounts for about 30% of all described mutations. Based on the results of the first mutation screening 
of ARX in individuals with mental retardation (Bienvenu et al., 2002), it was suggested that ARX 
mutations could be as common as fragile X syndrome among the mentally retarded population (Sherr 
2003). More recent studies, however, have shown that ARX mutations are not as frequent as initially 
suspected (Gronskov et al., 2004). The human ARX gene maps to chromosome Xp22.13 and is 
composed of five coding exons. It encodes a transcription factor expressed predominantly in the fetal 
and adult brain (Stromme et al., 2002b), thought to regulate essential processes during brain 
development, including neuronal proliferation, migration and differentiation (Kitamura et al., 2002; 
Friocourt et al., 2006). 
Autism is a behaviorally defined neurodevelopmental syndrome with a strong heritable component 
and marked genetic heterogeneity (Veenstra-Vanderweele et al., 2004). Monogenic disorders (e.g., 
fragile X syndrome, tuberous sclerosis complex, neurofibromatosis, various rare metabolic disorders) 
and chromosomal abnormalities are identified in about 10% of patients, but the underlying cause 
remains unknown in the majority of patients (Gillberg and Coleman 2000). The search for genetic 
variants conferring liability to autism using linkage and association analyses has failed to identify any 
definite genes (Veenstra-Vanderweele et al., 2004). The prevalence of autism is approximately four 
times higher in males than in females. The higher prevalence of males together with the description of 
cases with chromosomal aberrations involving the X chromosome (Vorstman et al., 2006), suggest the 
implication of X-linked genes in autism. Mutations in several X-linked genes have been identified in 
individuals with autism spectrum disorders. The most frequently reported genetic disorder in autism is 
the fragile X syndrome, involving CGG expansions in the FMR1 gene, found in about 2% of patients 
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with autism (Wassink et al., 2001). Other mutations of X-linked genes described in a few cases with 
autism spectrum disorders include MECP2 (Carney et al., 2003; Zappella et al., 2003), neuroligins 
NLGN3 and NLGN4X (Jamain et al., 2003), DMD (Wu et al., 2005), CDKL5 (Evans et al., 2005), and 
the creatine transporter SLC6A8 (Salomons et al., 2003). Together, these findings strongly suggest 
that other genes on the X chromosome are also potential candidates for autism. In particular, the ARX 
gene is a compelling candidate. Indeed, approximately 75% of subjects with autism also have mental 
retardation, and about 30% have epilepsy. The discovery of ARX mutations in patients with mental 
retardation, often associated with epilepsy and sometimes with autism (Nawara et al., 2006; Turner et 
al., 2002), suggests that ARX could be involved in other cases of autism. Thus, the aim of this study 
was to assess the frequency of ARX mutations in autism. We screened the ARX gene in 226 males 
with autism spectrum disorders and mental retardation; 42 of the patients had epilepsy. 
 
MATERIALS AND METHODS 
Patients 
A total of 226 males with an autism spectrum disorder and mental retardation were included in the 
study. They were recruited by the Paris Autism Research International Sibpair (PARIS) study at 
specialized clinical centers in seven countries (France, Sweden, Norway, Italy, Belgium, Austria, and 
the United States). There were 77 subjects from families with two or more affected siblings (45 with 
males only and 32 brother/sister pairs) and 149 sporadic cases. None of the familial cases was 
ascertained from known X-linked pedigrees with mental retardation or neurological disorders. 
Diagnoses were based on clinical evaluation by experienced clinicians, DSM-IV criteria, and the 
Autism Diagnostic Interview-Revised (ADI-R) (Lord et al., 1994). Among the patients studied, 218 had 
autism and 8 had pervasive developmental disorder not otherwise specified. Laboratory tests to rule-
out medical causes of autism included standard karyotyping, fragile X testing, and metabolic 
screening; brain imaging and EEG were performed when possible. Patients diagnosed with medical 
disorders such as fragile X syndrome or chromosomal abnormalities were excluded from the study. 
Forty-two patients had epilepsy and 6 had an abnormal EEG but no seizures. There were 198 
individuals of Caucasian origin, 12 Black, 2 Asian and 14 of mixed ethnicity. The local Research Ethics 
Boards reviewed and approved the study. Informed consent was obtained from all families 
participating in the study. 
ARX mutation analyses 
Genomic DNA was prepared from blood or lymphoblastoid cell lines. The complete ARX coding 
sequence including the exon-intron boundaries was amplified by PCR. Exon 2 was amplified in two 
overlapping fragments. Primer sequences were kindly provided by Prof Jozef Gécz (Stromme et al., 
2002b) or reported previously (Kato et al., 2004). The amplicons were screened for mutations by direct 
sequencing using the ABI BigDye Terminator sequencing kit (Applied Biosystems, Foster City, CA, 
USA) and an ABI 3100 sequencer (Applied Biosystems). 
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RESULTS 
Genomic DNA from 226 patients with autism spectrum disorders was screened for intragenic ARX 
mutations by sequencing analysis. No pathogenic mutations were identified in any sample. We 
identified one synonymous variant in exon 4, c.1347C>T (p.G449G), in 10 individuals. This variant has 
been described previously as a polymorphism (Gronskov et al., 2004; Kato et al., 2004). 
 
DISCUSSION 
Our results indicate that coding mutations in the ARX gene are not associated with autism in our 
family sample. Since our analysis was limited to the coding sequence of ARX, we cannot exclude that 
mutations in the promoter and other regulatory sequences may disrupt the activity of the ARX gene in 
some individuals with autism. Similarly, we cannot exclude the presence of duplications or deletions of 
ARX in our patients, as we did not perform quantitative analyses. Furthermore, the absence of coding 
changes does not preclude epigenetic abnormalities that might affect gene expression. 
Autism was described in 4 subjects among 50 mentally retarded males in 9 X-linked families with 
ARX mutations (Stromme et al., 2002a; Turner et al., 2002). They belonged to two families carrying 
the duplication c.428-451 dup(24 bp), which represents the most frequent mutation of the ARX gene 
found in mental retardation and epilepsy. Interestingly, the same mutation in other family members 
manifested as isolated mental retardation or was associated with dystonia, infantile spasms, 
generalized tonic-clonic seizures or ataxia, underlining the intrafamilial phenotypic variability 
associated with ARX mutations (Stromme et al., 2002a). Similarly, Nawara et al. (Nawara et al., 2006) 
reported 5 families with 19 affected patients with X-linked mental retardation carrying the 24-bp 
duplication; in one of the families, 2 of 4 affected males had autism. 
The precise prevalence of ARX mutations in mental retardation is at present unknown but is likely 
to be low. The first study to explore ARX in mental retardation found mutations in 7 of 9 extended 
families with mental retardation linked to Xp22.1, 2 of 148 families with two affected brothers and 1 of 
40 sporadic cases, suggesting that ARX mutations were a common cause of mental retardation 
(Bienvenu et al., 2002). The most recent estimates indicate that mutations in the ARX gene account 
for 9.5% of families with X-linked mental retardation but are less frequent in families with two affected 
brothers (2.2%) (Poirier et al., 2006). By contrast, the yield of ARX mutation analysis in sporadic males 
with mental retardation is extremely low. A recent Danish study screened exon 2 for two recurrent 
expansions of polyalanine tracts in 682 males with mental retardation, revealing only one putative 
mutation (Gronskov et al., 2004). Our negative findings after systematic sequence analysis of ARX in 
a large set of patients with autism and mental retardation, including 45 families with 2 or more affected 
brothers, 32 brother-sister pairs and 149 sporadic cases, are compatible with those reported for 
mental retardation.  
In conclusion, the results of the present study indicate mutations of the ARX gene are a very rare 
cause of autism, as previously shown for other X-linked genes, such as MECP2 (Carney et al., 2003; 
Zappella et al., 2003), NLGN3, and NLGN4X (Jamain et al., 2003), which have been screened in large 
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cohorts of patients with autism. Thus, with the exception of FMR1, the number of patients found to be 
mutated for each X-linked gene appears to be very low. In addition, our findings suggest that routine 
molecular screening of ARX is not indicated in families with two siblings with autism or in sporadic 
patients. 
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